The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Open accessAbstract
Summary: Immune checkpoint inhibitors are a new and effective class of cancer therapy, with ipilimumab being the most established drug in this category. The drugs’ mechanism of action includes promoting the effector T cell response to tumours and therefore increased autoimmunity is a predictable side effect. The endocrine effects of these drugs include hypophysitis and thyroid dysfunction, with rare reports of adrenalitis. The overall incidence of hypophysitis with these medications is up to 9%. Primary thyroid dysfunction occurs in up to 15% of patients, with adrenalitis reported in approximately 1%. The mean onset of endocrine side effects is 9 weeks after initiation (range 5–36 weeks). Investigation and/or screening for hypophysitis requires biochemical and radiological assessment. Hypopituitarism is treated with replacement doses of deficient hormones. Since the endocrine effects of immune checkpoint inhibitors are classed as toxic adverse events, most authors recommend both discontinuation of the immune checkpoint inhibiting medication and ‘high‐dose’ glucocorticoid treatment. However, this has been challenged by some authors, particularly if the endocrine effects can be managed (e.g. pituitary hormone deficiency), and the therapy is proving effective as an anticancer agent. This review describes the mechanism of action of immune checkpoint inhibitors and details the key clinical endocrine‐related consequences of this novel class of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis
Kazlauskaite, R., Evans, A. T., Villabona, C. V., Abdu, T. A. M., Ambrosi, B., Atkinson, A. B., Choi, C. H., Clayton, R. N., Courtney, C. H., Gonc, E. N., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0710 · Cited by 385
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179
Orlov, S., Salari, F., Kashat, L., & Walfish, P. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4560 · Cited by 134
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Ipilimumab-induced autoimmune adrenalitis
Min, L., & Ibrahim, N. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70031-7 · Cited by 112
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93
Cited by
Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
Caturegli, P., Di Dalmazi, G., Lombardi, M., Grosso, F., Larman, H. B., Larman, T., Taverna, G., Cosottini, M., & Lupi, I. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.08.020 · Cited by 381
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Sklar, C. A., Antal, Z., Chemaitilly, W., Cohen, L. E., Follin, C., Meacham, L. R., & Murad, M. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01175 · Cited by 224
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
Metadata
- Authors
- Joshi, M. N., Whitelaw, B. C., Palomar, M. T. P., Wu, Y., & Carroll, P. V.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2016-04-13
- Volume
- 85
- Issue
- 3
- Pages
- 331-339
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2305396859
- Cited by
- 220
- References
- 23
- FWCI
- 26.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.